MedPath

The effect of orlistat and metformin in the treatment of fatty liver disease

Phase 2
Conditions
Fatty liver.
nonalcoholic steatohepatitis
(K75.8)
Registration Number
IRCT2016031827097N1
Lead Sponsor
Ardebil University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
100
Inclusion Criteria

( Having Nonalcoholic fatty liver disease, the absence of diabetes mellitus, Fatty liver grade 2 and above, not having severe systemic disease, Lack of viral and autoimmune hepatitis, Lack of thyroid disease, do not have hyper triglyceridemia and Exclusion criteria: Having severe systemic disease, having viral hepatitis and autoimmune, having thyroid disease, Hyper triglyceridemia)

Exclusion Criteria

Not provided

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Triglyceride of blood. Timepoint: Befor and after the study. Method of measurement: Milligrams per deciliter.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath